Autres langues Astellas Pharma Inc.

Actions

4503

JP3942400007

Produits pharmaceutiques

Temps Différé Japan Exchange 07:14:44 07/10/2026			Varia. 5j.	Varia. 1 janv.
2 254,00 ^JPY	+0,47%		-2,87%	+7,69%

24/09	Astellas Pharma Inc. administre le traitement au premier patient dans une étude de phase 3 de setidegrasib chez des patients atteints d’un cancer du poumon non à petites cellules avancé avec mutation KRAS G12D déjà traité	CI
17/09	Astellas Pharma Inc. annonce des changements au sein de sa direction	CI

Autres langues

24/09	Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D- Mutated Advanced Non-Small Cell Lung Cancer
24/09	Astellas Pharma Inc. Doses First Patient In Phase 3 Study Of Setidegrasib In Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
17/09	Astellas Pharma Inc. Announces Executive Changes
01/09	Global pharma companies that have publicly announced Trump drug pricing agreements
01/09	White House Cuts Deal to Lower Prescription Drug Prices With Nine Companies
01/09	Astellas Pharma Inc. Enters Voluntary Agreement with U.S. Government Supporting Affordable Access to Medicines
31/08	Trump announces new round of drug-pricing deals
31/08	Kyntra Bio Cuts Royalty Payments to NQ Project Phoebus for Accelerated Upfront Payment
31/08	Trump Announces Nine New Drug Pricing Deals With Pharmaceutical Companies
31/08	BeOne unterzeichnet Vereinbarung mit US-Regierung zu Medikamentenpreisen
31/08	Trump Administration Reaches Most-Favored-Nation Drug Pricing Deals With 9 Companies
31/08	Trump administration to announce drug pricing deals
28/08	Winst van Astellas mogelijk verdubbeld, maar kan het aandeel marktscepticisme afschudden?
27/08	Astellas' Profits May Have Doubled, But Can It Outrun the Street's Skepticism?
25/08	Astellas Pharma Inc. Doses First Patient In Phase 3 Study Of ASP2138 In Combination With Chemotherapy And Pembrolizumab As First-Line Treatment In Adults With Locally Advanced Unresectable Or Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma
10/08	AbCellera's menopause drug cuts hot flashes in mid-stage trial, shares surge
06/08	South African Patent Ruling In Favour Of Astellas Pharma
06/08	Japan Earnings Wrap: Kao, Astellas Pharma Rise; Taiyo Yuden Declines
05/08	Merck's Keytruda Gets Canadian Approval to Treat Muscle-Invasive Bladder Cancer
05/08	Astellas Pharma's Profit Soars 107% in Fiscal Q1
05/08	Astellas Pharma Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026
13/07	Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug
10/07	Health Care Down on Rotation Back to Tech - Health Care Roundup
10/07	Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA
10/07	Pfizer Poised for Mixed Second Quarter, RBC Says